http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017095476-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704 |
| filingDate | 2016-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d079cfa501e097c3ec40e57275c2efa6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159ceab4e005e3cc9ab364d2fb479268 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f02b6bf55b0b76b9cf1100ed38ba8919 |
| publicationDate | 2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017095476-A |
| titleOfInvention | Use of laquinimod to reduce fatigue, improve functional status and improve quality of life in patients with multiple sclerosis |
| abstract | To reduce or inhibit the progression of the level of fatigue in a human patient with multiple sclerosis, to improve or suppress the deterioration of the functional state of a human patient with multiple sclerosis, and to a human patient with multiple sclerosis Providing a method for improving or suppressing the deterioration of overall health. An oral form of laquinimod, or a pharmaceutically acceptable salt thereof, used to reduce or inhibit the progression of the level of fatigue in a human patient with multiple sclerosis, wherein the method of use is Multiple sclerosis comprising orally administering laquinimod or a pharmaceutically acceptable salt thereof to the human patient, thereby reducing or inhibiting the progression of fatigue levels in the multiple sclerosis human patient. Of improving or suppressing the deterioration of the functional status and overall health of patients with dementia. [Selection] Figure 1 |
| priorityDate | 2010-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 249.